

# CURRICULUM VITAE

---

**Name:** Filippos  
**Surname:** Koinis  
**Title:** MD, PhD  
**Date of birth:** 11/2/1980 (D/M/Y)  
**Email Address:** [phillipkoinis@gmail.com](mailto:phillipkoinis@gmail.com)

## CURRENT POSITION

- a. Consultant Medical Oncologist at Iatriko Athinon
- b. Scientific Associate, Member of the Molecular Carcinogenesis Group, Laboratory of Histology and Embryology Medical School, National and Kapodistrian University of Athens

### Past training in brief

| INSTITUTION AND LOCATION  | DEGREE                         | FIELD OF STUDY                     |
|---|--------------------------------|------------------------------------|
| Department of Medicine, School of Health Sciences, University of Thessaly, Larisa, Greece | MD                             | Medicine                           |
| University Hospital of Heraklion, Greece  | Residency – Medical oncologist | Medical Oncology                   |
| Laboratory of Cancer Cell Biology, School of Medicine, University of Crete                | Postdoctoral Fellow            | Cancer Immunology/NSCLC            |
| Comprehensive Cancer Center Vienna in the General Hospital (AKH) of Vienna                | Clinical Research Fellow       | Targeted Treatment/Clinical Trials |
| UT MD Anderson Cancer Center, Houston, USA  | Postdoctoral Fellow            | Prostate cancer                    |

## EDUCATION AND HONORS

2004: Medical degree-Awarded the degree of the Department of Medicine, School of Health Sciences, University of Thessaly, **with average grade 8.78, “Excellent”**. Duration of studies: 12 semesters (minimum length of studies: 12 semesters)

**Honors:** Scholarship from the State Scholarships Foundation (I.K.Y.) (Achieved highest graduation score in Medical School of Thessaly). Honorary vocalization of the Hippocratic Oath

1998-2004: Medical School of Thessaly, Greece

**Honors:** Scholarships from the State Scholarships Foundation (I.K.Y.) for pre-graduate performances for the academic years 2001-2002 and 2003-2004

## RESIDENCY AND EMPLOYMENT

- 2004 - 2006 Medical service in rural areas in Greece
- 2006 - 2007 Medical service in Greek military
- 2008 - 2010 Resident (Internal Medicine) at ‘Evangelismos’ General Hospital of Athens, Greece
- 2010 - 2011 Resident (Hematology) at ‘Evangelismos’ General Hospital of Athens, Greece
- 2011 - 2014 Resident (Medical Oncology) at General University Hospital of Heraklion, Greece
- 2012 Trainee for 4 months in the Laboratory of Cancer Cell Biology, School of Medicine, University of Crete
- 2014 License to use the Medical Specialty Qualification of Medical Oncology, Greece
- 2015 - 2016 Postdoctoral Fellow at the Laboratory of Cancer Cell Biology, School of Medicine, University of Crete, Greece
- 2016 Clinical Research Fellow at the Comprehensive Cancer Center Vienna in the General Hospital (AKH) of Vienna, Austria
- 2016 - 2017 Postdoctoral Fellow at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA
- 2018 Consultant Medical Oncologist at Iatriko Athinon

## RESEARCH

### I. Translational research

- 2016 – 2017: Postdoctoral fellow at the Department of Genitourinary Medical Oncology at MD Anderson Cancer Center under the guidance of Dr Gary Gallick
- 2015 – 2016: Postdoctoral fellow at the Laboratory of Cancer Cell Biology, School of Medicine, University of Crete for the Hellenic Oncology Research Group
- 2013: PhD Thesis entitled: “Influence of chemotherapy with or without Bevacizumab on the negative immune-modulators in NSCLC patients”
- 2013: Preceptorship in Clinical and Translational Cancer Research – Integrated Management of Cancer Patients, Medical School – University of Crete, Crete
- 2012: Training for 4 months in the Laboratory of Cancer Cell Biology, School of Medicine, University of Crete

### II. Clinical research

- 2016: Clinical research fellow at the Comprehensive Cancer Center Vienna in the General Hospital (AKH) of Vienna
- 2016: Updated Training for the ICH-Good Clinical Practice guidelines
- 2013-present: Development of trial proposals and protocols presented at the EORTC Young Investigators meetings or the Hellenic Oncology Research Group meetings
- 2011-present: CRA in various Phase I, II, III or IV international or national multicenter clinical trials. Actively involved in the management of the patients enrolled in these trials, as part of my residency.
- Tumor types: Lung Cancer, Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Gastrointestinal Cancer, Sarcoma, Melanoma, Hepatocellular Carcinoma, Renal cancer, Prostate cancer, Ovarian Cancer, BCC Cancer

## HONORS

|             |  |
|-------------|--|
| 2001 - 2002 | Scholarship from the State Scholarships Foundation (I.K.Y.) for pre-graduate performance   |
| 2003 - 2004 | Scholarship from the State Scholarships Foundation (I.K.Y.) for pre-graduate performance   |
| 2004        | Achieved highest graduation score in Medical School of Thessaly.<br>Honorary vocalization of the Hippocratic Oath  |
| 2014        | Passed the Hellenic Society of Medical Oncology (HESMO) Examination held on May 2014 in Athens, Greece, achieving a score of 84.3/100  |
| 2014:       | Completed the 2-year Post-graduate Training Program on Medical Oncology and Cancer Biology (EAKO) organized by the Hellenic Society of Medical Oncology (HESMO)              |
| 2014:       | Participation in the 13th ESO-ESMO Masterclass in Clinical Oncology, held in Ermatingen, Switzerland   |
| 2014        | Passed the European Society of Medical Oncology (ESMO) Examination in Madrid, Spain, achieving a score of 88%, ranking in the 4th place, worldwide ( <i>ESMO certified</i> ) |
| 2016        | Clinical Research Fellowship, Comprehensive Cancer Center Vienna, General Hospital (AKH) of Vienna   |
| 2016        | Translational Research Fellowship, Hellenic Society of Medical Oncology  |
| 2016:       | Updated Training for the ICH-Good Clinical Practice guidelines   |

## MEDICAL LICENCURE

To practice the Medical Profession since 2004

Medical Specialty Qualification of Medical Oncology since 2014

Registered at General Medical Council (GMC), UK, since 2016

## TEACHING EXPERIENCE

- 2014: Supervision of medical students on a project to set up a clinical trial on pazopanib in SCLC at the 22<sup>nd</sup> Post-graduate Congress on Medical Oncology, held in Heraklion, Crete on 13<sup>th</sup>-16<sup>th</sup> November 2014
- 2014: Bi-weekly didactic rounds for medical students at the University of Crete in Internal Medicine
- 2014: Participation in the writing of the educational material and the theoretical training of the ESPA program number KA3643 Subunit 1: Telesforos. This was a training program for medical doctors and nurses that work in the primary care health system regarding the support of cancer patients during treatment
- 2014: Training of younger colleagues, as a chief Fellow, at the Department of Medical Oncology of the University Hospital of Heraklion
- 2014: Participation, as a speaker, in seminars, journal club meetings, case studies discussions or presenting reviews on various topics of medical oncology in the Department of Medical Oncology of University of Crete
- 2007: Monthly lectures at soldiers regarding major health issues, as part of my military service

## ABSTRACTS AND POSTER PRESENTATIONS IN NATIONAL AND INTERNATIONAL CONGRESSES

### A. National

1. **Docetaxel και Bevacizumab ως χημειοθεραπεία 1ης γραμμής σε ηλικιωμένους ασθενείς με εκτεταμένο και μεταστατικό Μη-Μικροκυτταρικό Καρκίνο Πνεύμονα (ΜΜΚΠ): Πρώιμα αποτελέσματα μιας Πολυκεντρικής Μελέτης Φάσης II.**

Κοΐνης Φ., Βαμβακάς Α., Καραμπεάζης Α., Πολύζος Α., Αγκελάκη Σ., Κεντεποζίδης Ν., Κωτσάκης Α., Πάλλης Α., Κοντοπόδης Ε., Μποζιονέλου Β., Γεωργούλιας Β.

*19ο Συνέδριο Κλινικής Ογκολογίας ΕΟΠΕ, Αθήνα, 25-27 Απριλίου, 2013*

2. **Προγνωστική/Προβλεπτική σημασία των Άωρων Μυελοειδών Κυττάρων (MDSCs) και των ρυθμιστικών Τ κυττάρων (Tregs) σε ασθενείς με μη-μικροκυτταρικό καρκίνο του πνεύμονα (ΜΜΚΠ).**

Βέτσικα Ε.Κ., Σκαλιδάκη Ε., Αγγουράκη Δ., Κοΐνης Φ., Κουτουλάκη Α., Μαυρουδής Δ., Γεωργούλιας Β., Κωτσάκης Α.

*19ο Συνέδριο Κλινικής Ογκολογίας ΕΟΠΕ, Αθήνα, 25-27 Απριλίου, 2013*

**3. Μία μελέτη φάσης 2 του pazopanib ως 2ης γραμμής θεραπεία σε ασθενείς με μικροκυτταρικό καρκίνο πνεύμονα: Πρώιμα αποτελέσματα σε ασθενείς με ευαίσθητη νόσο.**

Κωτσάκης Α, Κεντεποζίδης Ν, Κοΐνης Φ, Καραβασίλης Β, Βαρθαλίτης Ι, Περουκίδης Σ, Δερμιτζάκη Ε.Κ, Ζήρας Ν, Ρές Ε, Μαυρουδής Δ, Γεωργούλιας Β, Αγγελάκη Σ.

20ο Συνέδριο Κλινικής Ογκολογίας ΕΟΠΕ, Αθήνα, 2ο Ελληνικό Συνέδριο Ογκολογίας (ΕΣΟ) (20ο ΠΣΚΟ και 14ο ΠΣΑΟ), Θεσσαλονίκη, 10- 12 Απριλίου 2014.

**4. A high frequency of a circulating monocytic subpopulation of myeloid-derived suppressor cells predicts worst clinical outcome in untreated non-small lung cancer patients.**

Vetsika EK, Koinis F, Gioulmpasani M, Aggouraki D, Koutoulaki A, Skalidaki E, Mavroudis D, Georgoulas V, Kotsakis

21ο Συνέδριο Κλινικής Ογκολογίας ΕΟΠΕ, Αθήνα, 23-25 Απριλίου 2015.

**5. Προγνωστική αξία της ανίχνευσης των CEACAM5mRNA και CK19mRNA θετικών κυττάρων στο περιφερικό αίμα ασθενών με Μη Μικροκυτταρικό Καρκίνο του Πνεύμονα.**

Μεσσαριτάκης Ι., Αποστολάκη Σ., Μηλάκη Γ., Κοΐνης Φ., Σουγκλάκος Ι., Περράκη Μ., Σφακιανάκη Μ., Μανούρας Α., Γεωργούλιας Β.

21ο Συνέδριο Κλινικής Ογκολογίας ΕΟΠΕ, Αθήνα, 23-25 Απριλίου 2015.

**6. Κάπνισμα και κατανάλωση αλκοόλ σε ασθενείς με κακοήθη νεοπλάσματα παχέος εντέρου. Δεδομένα δύο δεκαετιών από το Κέντρο Καταγραφής Καρκίνου Κρήτης.**

Κοΐνης Φ., Σηφάκη-Πιστόλλα Δ., Χατζέα Β-Ε, Τζανάκης Ν., Γεωργούλιας Β., Λιονής Χ.

3<sup>ο</sup> Ελληνικό Συνέδριο Ογκολογίας, Ιωάννινα, 21-23 Απριλίου 2016.

**7. Πρόβλεψη της μελλοντικής διακύμανσης των κακοήθων νεοπλασμάτων βρόγχων και πνεύμονα στην Κρήτη.**

Σηφάκη-Πιστόλλα Δ., Κοΐνης Φ., Χατζέα Β-Ε, Τζανάκης Ν., Γεωργούλιας Β., Λιονής Χ.

3<sup>ο</sup> Ελληνικό Συνέδριο Ογκολογίας, Ιωάννινα, 21-23 Απριλίου 2016.

**8. Mechanism of FGFR-1 overexpression in prostate cancer.**

Koinis F, Parikh NU, Song JH, Matthaios D, Logothetis CJ, Gallick GE.

23<sup>ο</sup> Ελληνικό Συνέδριο Κλινικής Ογκολογίας 2017, Αθήνα, 27-29 Απριλίου 2017.

## **B. International**

- 1. A phase I trial of the carboplatin/gemcitabine doublet as first-line treatment for elderly patients with squamous non-small-cell lung cancer (NSCLC).**

A.G. Pallis, L. Vamvakas, A. Karampeazis, S. Agelaki, V. Chandrinou, A. Polyzos, F. Koinis, D. Stoltidis, N. Vardakis, V. Georgoulas

*Advances and Perspectives in Geriatric Oncology-ATHENS INTERNATIONAL SYMPOSIUM, Athens, 17-18 February 2012*

- 2. A phase II study of the combination of bevacizumab with cytotoxic chemotherapy as first line treatment, in older patients with advanced/metastatic NSCLC (non-squamous).**

A.G. Pallis, L. Vamvakas, A. Karampeazis, A. Polyzos, S. Aggelaki, N. Kentepozidis, I. Boukovinas, A. Kotsakis, E. Papadimitraki, F. Koinis, V. Georgoulas

*12<sup>th</sup> annual SIOG meeting, Manchester, United Kingdom, October 25-27, 2012*

- 3. Docetaxel plus bevacizumab as first-line treatment in older patients with non-squamous, advanced and metastatic non-small-cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial from the Hellenic Oncology Research Group.**

A.Karampeazis, L.Vamvakas, A.G.Pallis, A.Polyzos, S.Agelaki, N.Kentepozidis, I.Boukovinas, A.Kotsakis, E.Papadimitraki, F.Koinis, V.Georgoulas.

*2nd International Symposium on Thoracic and Upper Aerodigestive Malignancies, Athens, 4-6 April 2013*

- 4. Increased levels of Myeloid-Derived Suppressor Cells are associated with clinical outcome in Non-Small Cells Lung Cancer (NSCLC) patients.**

Vetsika E.-K., Koinis F., Aggouraki D., Koutoulaki A., Mavroudis D., Georgoulas V., Kotsakis A.

*2nd International Symposium on Thoracic and Upper Aerodigestive Malignancies, Athens, 4-6 April 2013*

- 5. Phase II trial of mFOLIRI plus Bevacizumab as 1st line treatment in elderly patients with metastatic colorectal cancer.**

L Vamvakas, A Karampeazis, N Kentepozidis, A Christopoulou, K Kalbakis, F Koinis, El Papadimitraki, D Hatzidaki, V Georgoulas, J Souglakos

*ESMO 15th World Congress on Gastrointestinal Cancer, Barcelona, 3-6 July 2013*

**6. A pilot phase II trial of cabazitaxel in patients with metastatic NSCLC progressing after docetaxel-based treatment: preliminary results.**

A. Kotsakis, N. Kentepozidis, S. Agelaki, E. Kontopodis, F. Koinis, I. Mountzios, V. Karavassilis, P. Koliou, L. Vamvakas, V. Georgoulas

*European Cancer Congress 2013 (ECCO-ESMO-ESTRO), Amsterdam, Netherlands, 27 September - 1 October 2013*

**7. A retrospective analysis regarding the parameters which influence the administration of adjuvant chemotherapy to elderly patients (>70 years) with stage II or III colon cancer in the daily clinical practice.**

N. Asimakopoulou, P. Papakonstantinou, J. Souglakos, A. Karampeazis, Z. Saridaki, F. Koinis, A. Matikas, C. Nikolaou, V. Georgoulas, L. Vamvakas

*13th annual SIOG meeting, Copenhagen, Denmark, 24-26 October, 2013*

**8. High levels of circulating immunosuppressive cells predict worst clinical outcome in Non-Small Lung Cancer (NSCLC) patients.**

E. K. Vetsika, F. Koinis, D. Aggouraki, A. Koutoulaki, D. Mavroudis, V. Georgoulas, A. Kotsakis

*15<sup>th</sup> WORLD CONFERENCE ON LUNG CANCER (IASLC 2013), Sydney, Australia, 27-31 October 2013*

**9. A multicenter phase I-II trial of weekly paclitaxel and carboplatin plus bevacizumab in women with triple-negative metastatic breast cancer.**

E. Saloustros, A. Polyzos, F. Koinis, D. Kalapanida, Ch. Christophyllakis, N. Kenteposidis, K. Kalbakis, S. Agelaki, V. Georgoulas, D. Mavroudis

*ICACT-25<sup>th</sup> International Congress on Anti-Cancer Treatment, Paris, France, 4 - 6 February 2014*

**10. High frequency of a circulating monocytic subpopulation of myeloid-derived suppressor cells predicts worst clinical outcome in untreated non-small lung cancer patients.**

E-K. Vetsika, F. Koinis, M. Gioulmpasani, D. Aggouraki, A. Koutoulaki, E. Skalidaki, D. Mavroudis, V. Georgoulas, A. Kotsakis.

*AACR, San Diego, CA, April 5-9 2014*

**11. Effect of chemotherapy on the myeloid-derived suppressor cells (MDSCs) percentages in the peripheral blood of advanced non-small cell lung cancer patients.**

E-K Vetsika, M Gioulmpasani, E Skalidaki, A Katsarou, F Koinis, D Aggouraki, A Koutoulaki, D Mavroudis, V Georgoulas, A Kotsakis

*Immunology 2015, New Orleans, Louisiana, USA, 8-12 May 2015*



**12. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pretreated with a non-platinum-based regimen in the first-line setting: A randomized phase II study of the Hellenic Oncology Research Group (HORG).**

N. K. Kentepozidis, P. Economopoulou, C. Christophyllakis, L. Chelis, A. Polyzos, N. Vardakis, F. Koinis, C. Nikolaou, V. Georgoulas, A. Kotsakis; Hellenic Oncology Research Group (HORG), Athens, Greece

*2015 ASCO Annual Meeting, Chicago, USA, 29 May-2 June 2015*

*Abstract Number: e19044, Citation: J Clin Oncol 33, 2015 (suppl; abstr e19044)*

**13. PKM2 and CD44 tumoral expression to predict the effectiveness of front-line paclitaxel and carboplatin chemotherapy in epithelial ovarian cancer.**

C. Papadaki, S. Pontikakis, E. Lagoudaki, M. Trypaki, F. Koinis, M. Tzardi, L. Giannikaki, M. Sfakianaki, A. Kalykaki, D. Mavroudis, V. Georgoulas, I. Souglakos

*2015 ASCO Annual Meeting, Chicago, USA, 29 May-2 June 2015*

*Abstract Number: e16564, Citation: J Clin Oncol 33, 2015 (suppl; abstr e16564)*

**14. Long term clinical benefit of EGFR wt in advanced NSCLC patients treated for long time with salvage erlotinib. A retrospective analysis.**

A. Kotsakis, A. Voutsina, A. Kalikaki, N. Kentepozidis, F. Koinis, A. Pallis, P. Katsaounis, K. Kalbakis, K.E. Dermizaki, D. Hatzidaki, V. Georgoulas

*16th World Conference on Lung Cancer, Denver, Colorado, USA, September 6 - 9 2015*

*Abstract ID: 687, P1.01-014*

**15. Prognostic Significance of CK19mRNA Positive Cells in the Peripheral Blood of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC).**

I. Messaritakis, S. Apostolaki, G. Milaki, F. Koinis, L. Manouras, M. Perraki, V. Georgoulas, A. Kotsakis

*16th World Conference on Lung Cancer, Denver, Colorado, USA, September 6 - 9 2015*

**16. The proliferation index of circulating tumor cells (CTCs) is not influenced by the administration of adjuvant chemotherapy in early breast cancer (BC) and seems to reflect Ki67 expression of the primary tumor.**

S. Agelaki, M. Spiliotaki, A. Spanaki, L. Kassiou, M. Tzardi, F. Koinis, M. Kafousi, V. Georgoulas, D. Mavroudis

*2015 San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, December 8-12 2015*

**17. TTF1- and CD56-expressing circulating tumor cells (CTCs) in the peripheral blood of patients with small cell lung cancer (SCLC).**

I. Messaritakis, E. Politaki, S. Apostolaki, K-E. Dermitzaki, F. Koinis, E. Lagoudaki, A. Kotsakis, V. Georgoulas, J. Souglakos

*10th ISMRC International Symposium on Minimal Residual Cancer: Liquid Biopsy in Cancer Diagnostics and Treatment, Hamburg, Germany, March 19-21 2016*

**18. Lung Cancer Epidemiology: Two Decades' records collected by the Cancer Registry of Crete.**

D. Sifaki-Pistolla, I. Tsiligianni, V.E Chatzea, F. Koinis, N. Tzanakis, V. Georgoulas, C. Lionis

*8<sup>th</sup> IPCRG World Conference, Amsterdam, Holland, May 25-28 2016*

**19. Effect of 2nd line Pazopanib (PZN) on the number and phenotype of CTCs in patients with small cell lung cancer.**

I. Messaritakis, E. Politaki, S. Apostolaki, M. Plataki, F. Koinis, N. Vovolinis, K. Dermitzaki, V. Georgoulas, A. Kotsakis

*2016 ASCO Annual Meeting, Chicago, IL, USA, June 3-7 2016*

**20. Salvage treatment of relapsed/refractory Small cell lung cancer with Pazopanib: A Hellenic Oncology Research Group's (HORG) phase II study.**

A. Kotsakis, V. Karavasilis, S. Agelaki, N. Kentepozidis, S. Peroukidis, E. Samantas, Ch. Christofillakis, E.K. Dermitzaki, F. Koinis, E. Hartabilas, G. Fountzilias, E. Prinarakis, V. Georgoulas

*2016 ASCO Annual Meeting, Chicago, IL, USA, June 3-7 2016*

**21. Evaluation of PD-1 and PD-L1 expression on CTCs isolated from non-small cell lung cancer (NSCLC) tumor patients.**

G. Kallergi, D. Aggouraki, P. Katsarlinos, E.K. Vetsika, E. Lagoudaki, F. Koinis, A. Koutsopoulos, V. Georgoulas, A. Kotsakis

*ESMO Congress, Copenhagen, Denmark, 7-11 October 2016*

**22. Predictive/Prognostic value of circulating regulatory T cell subset in untreated non-small lung cancer patients.**

E.-K. Vetsika, F. Koinis, A. Katsarou, M. Gioulbasani, D. Aggouraki, N. Kentepozidis, V. Georgoulas, A. Kotsakis.

*ESMO Congress, Copenhagen, Denmark, 7-11 October 2016*

**23. Towards developing evidence-based GIS-driven infrastructure for cancer surveillance in Greece.**

D. Sifaki-Pistolla, F. Koinis, VE. Chatzea, S. Lionakis, K. Epitropaki, E. Vasilaki, T. Romanidou, M. Kouroupi, E. Frouzi, V. Georgoulas, C. Lionis, P. Kyriakidis, S. Aggelaki, N. Tzanakis

*9th European Public Health Conference, Vienna, Austria, 9 - 12 November 2016*

**24. Lung cancer geographical variation in Crete, 1992-2013. Insights from a population-based registry.**

D. Sifaki-Pistolla, F. Koinis, V. Georgoulas, C. Lionis, P. Kyriakidis, S. Aggelaki, N. Tzanakis

*9th European Public Health Conference, Vienna, Austria, 9 - 12 November 2016*

**25. High frequencies of PD-1+CD8+ T cells are correlated with PD-L1+ circulating tumor cells (CTC) and have predictive/prognostic value in non-small cell lung cancer (NSCLC) patients.**

Vetsika E.-K., Kallergi, G. Aggouraki D., Lyristi Z., Katsarlinos P., Koinis F., Georgoulas V., Kotsakis A.

*31st Annual Meeting of Society for Immunotherapy of Cancer, Gaylord National Hotel & Convention Center, National Harbor, Maryland, USA, November 9-13 2016*

**26. Effect of Anti-PD-1 Therapy on Immune Cells in the Peripheral Blood of Non-Small Cell Lung Cancer (NSCLC) patients.**

E-K Vetsika, D. Aggouraki, Z. Lyristi, F. Koinis, V. Georgoulas, A. Kotsakis

*17th World Conference on Lung Cancer, Vienna, Austria, December 4- 7 2016*

**27. Ki67-positive CTCs are associated with early disease relapse in patients with early breast cancer undergoing adjuvant chemotherapy.**

S. Agelaki, M. Spiliotaki, E. Politaki, A. Spanaki, L. Kassiou, F. Koinis, V. Georgoulas, D. Mavroudis

*2016 San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, December 6-10 2016*

**28. Prognostic value of PD-L1+CD4+ T cells in non-small cell lung cancer (NSCLC) patients treated with a PD-1 inhibitor.**

Vetsika E.-K., Aggouraki D., Lyristi Z., Koinis F., Georgoulas V., Kotsakis A.

*ASCO-SITC Clinical Immuno-Oncology Symposium, Orlando, FL, USA, February 23-25 2017*

**29. Changes of the peripheral blood immune cells during treatment of non-small cell lung cancer (NSCLC) patients with Nivolumab.**

Aggouraki D., Vetsika E.-K., Kallergi G., Lyrusti Z., Koinis F., Georgoulas V., Kotsakis A.

*4th Symposium on Thoracic and Upper Aerodigestive Malignancies, Athens, Greece, 6-9 April 2017*

**30. Dynamic changes of phenotypically different circulating tumor cell sub-populations in patients with recurrent/refractory Small Cell Lung Cancer treated with pazopanib.**

Ip Messaritakis, E Politaki, F. Koinis, D Stoltidis, S. Apostolaki, M. Plataki, E.K Dermitzaki, V Georgoulas, A Kotsakis

*4th Symposium on Thoracic and Upper Aerodigestive Malignancies, Athens, Greece, 6-9 April 2017*

**31. Second line pazopanib in patients with relapsed/refractory Small Cell Lung Cancer: A multicenter phase II study of the Hellenic Oncology Research Group.**

F. Koinis, S. Agelaki, V. Karavassilis, N. Kentepozidis, E. Samantas, S. Peroukidis, P. Katsaounis, E. Hartabilas, I. Varthalitis, I. Messaritakis, G. Fountzilias, V. Georgoulas, A. Kotsakis

*4th Symposium on Thoracic and Upper Aerodigestive Malignancies, Athens, Greece, 6-9 April 2017*

**32. PD-L1 and PD-1 expression on Circulating Tumor Cells (CTCs) in advanced non-small cell lung cancer (NSCLC) patients treated with Nivolumab.**

G. Kallergi, E.-K. Vetsika, D. Aggouraki, E. Lagoudaki, A. Koutsopoulos, F. Koinis, P. Katsarlinos, M. Trypaki, C. Stournaras, V. Georgoulas, A. Kotsakis

*4th Symposium on Thoracic and Upper Aerodigestive Malignancies, Athens, Greece, 6-9 April 2017*

**33. Evaluation of PD-L1/PD-1 on Circulating Tumor Cells (CTCs) and on primary tumor in advanced non-small cell lung cancer (NSCLC).**

G. Kallergi, E.K. Vetsika, D. Agouraki, E. Lagoudaki, A. Koutsopoulos, F. Koinis, P. Katsarlinos, M. Trypaki, C. Stournaras, V. Georgoulas, A. Kotsakis

*AACR Annual Meeting 2017, Walter E. Washington Convention Center, Washington, D.C., USA, April 1 - 5, 2017*

**34. Effect of anti-PD-1 therapy on immune cells in the peripheral blood of non-small cell lung cancer (NSCLC) patients.**

Vetsika E.-K, Kallergi G, Aggouraki D, Lyrusti Z, Koinis F, Georgoulas V, Kotsakis A.

*AACR Annual Meeting 2017, Walter E. Washington Convention Center, Washington, D.C., USA, April 1 - 5, 2017*

**35. Smoking behaviour of lung and colorectal cancer patients during and after diagnosis. Which factors hinder smoking cessation?**

V-E.Chatzea, D.Sifaki-Pistolla, G.Pistolla, F.Koinis, N.Tzanakis, V.Georgoulis, CLionis.

*ENSP International Conference on Tobacco Control 2017, Athens, May 24-26, 2017*

**36. Optimal locations of establishing smoking cessation services for cancer patients in Crete, Greece.**

D. Sifaki-Pistolla, V-E. Chatzea, G. Pistolla, F. Koinis, N. Tzanakis, V. Georgoulis, C Lionis.

*ENSP International Conference on Tobacco Control 2017, Athens, May 24-26, 2017*

**37. Deprivation and smoking trends among lung cancer patients before and after the Greek economic crisis. Insights from the Cancer Registry of Crete.**

D. Sifaki-Pistolla, C. Lionis, V-E. Chatzea, F. Koinis, V. Georgoulis, N. Tzanakis.

*ENSP International Conference on Tobacco Control 2017, Athens, May 24-26, 2017*

**38. “New treatments in Oncology: clinical practice regarding the management of Adverse Events (AEs)”: results from a survey conducted by the Hellenic Group of Young Oncologists (HeGYO).**

F. Koinis, M. Lontos, G. Chatsidis, K. Kamposioras, G. Papaxoinis, M. Nikolaou, K. Tsigaridas, E. Voulgaris, E. Pantavou, G. Aravantinos, A. Ardavanis, I. Boukovinas, E. Galani, S. Angelaki, I. Mountzios, Z. Saridaki, I. Varthalitis, N. Tsoukalas  
Final publication number: 1462P

*ESMO Congress 2017, Madrid, Spain, 8 - 12 Sep 2017*

**39. Cancer incidence and mortality trends in Crete, Greece during the last two decades (1992-2013): Results from the cancer registry of Crete.**

V. Chatzea, D. Sifaki-Pistolla, F. Koinis, E. Saloustris, L. Vamvakas, G. Pitsoulis, N. Tzanakis, D. Mavroudis, V. Georgoulis, C. Lionis.

Final publication number: 1459P

*ESMO Congress 2017, Madrid, Spain, 8 - 12 Sep 2017*

## **Oral presentations**

**1. Effect of anti-VEGF therapy on MDSCs’ population in the peripheral blood of non-small cell lung cancer (NSCLC) patients**

F. Koinis, E-K. Vetsika, M. Gioulbasani, D. Aggouraki, A. Koutoulaki, L. Vamvakas, D. Mavroudis, V. Georgoulis, A. Kotsakis

*16th World Conference on Lung Cancer, Denver, Colorado, USA, September 6 - 9 2015*

*Abstract ID: 689*

**2. Pazopanib as second line treatment of platinum sensitive SCLC patients: A multicenter phase II trial of the Hellenic Oncology Research Group**

A. Kotsakis, V. Karavasilis, S. Agelaki, N. Kentepozidis, S. Peroukidis, E. Samantas, C. Christophyllakis, E-K. Dermizaki, F. Koinis, G. Fountzilias, V. Georgoulas; Hellenic Oncology Research Group (HORG), Athens, Greece

*16th World Conference on Lung Cancer, Denver, Colorado, USA, September 6 - 9 2015*

**3. Colorectal cancer in Crete: new data analysis and prediction of future fluctuation**

D. Sifaki-Pistolla, K. Eleni, V. Chatzea, F. Koinis, N. Tzanakis, G. Vassilios, C. Lionis

*11th Congress on Management, Economics and Health, Athens, Greece, Dec 10 2015*

**4. Η Γεω-επιδημιολογία του Καρκίνου στην Κρήτη: Υφιστάμενη κατάσταση και πρόβλεψη της μελλοντικής διακύμανσης.**

Σηφάκη-Πιστόλλα Δ., Χατζέα Β-Ε, Κοΐνης Φ., Βαμβακάς Λ., Μαυρουδής Δ., Γεωργούλιας Β., Λιονής Χ.

*18<sup>ο</sup> Παγκρήτιο Ιατρικό Συνέδριο, Ρέθυμνο, Ελλάδα, Νοέμβριος 4 2016*

**Award «ΟΔΥΣΣΕΑ ΚΑΛΛΙΓΙΑΝΝΗ»**

## **PUBLICATIONS IN CITED JOURNALS**

**1. Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).**

Koinis F, Polyzos A, Christopoulou A, Zafeiriou Z, Emmanouilidis C, Papadimitraki E, Kalykaki A, Kalbakis K, Samonis G, Georgoulas V.

*Cancer Chemotherapy and Pharmacology, 2014 Apr;73(4):819-25. doi: 10.1007/s00280-014-2411-2. Epub 2014 Feb 15.*

**2. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.**

Vetsika EK, Koinis F, Gioulbasani M, Aggouraki D, Koutoulaki A, Skalidaki E, Mavroudis D, Georgoulas V, Kotsakis A.

<sup>1</sup>Eleni-Kyriaki Vetsika and Filippos Koinis contributed equally to this work.

*J Immunol Res. 2014;2014:659294. doi: 10.1155/2014/659294. Epub 2014 Nov 11.*

**3. Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy.**

Spiliotaki M, Mavroudis D, Kapranou K, Markomanolaki H, Kallergi G, Koinis F, Kalbakis K, Georgoulas V, Agelaki S.

*Breast Cancer Res. 2014 Nov 29;16(6):485. doi: 10.1186/s13058-014-0485-8.*

**4. Nutritional assessment in overweight and obese patients with metastatic cancer: Does it make sense?**

Gioulbasanis I, Martin L, Baracos VE, Thézénas S, Koinis F, Senesse P.

*Annals of Oncology*. 2015 Jan;26(1):217-21. doi: 10.1093/annonc/mdu501. Epub 2014 Oct 30.

**5. Prognosis in advanced lung cancer - A prospective study examining key clinicopathological factors.**

Simmons CP, Koinis E, Fallon MT, Fearon KC, Bowden J, Solheim TS, Gronberg BH, McMillan DC, Gioulbasanis I, Laird BJ.

*Lung Cancer*. 2015 Jun;88(3):304-9. doi: 10.1016/j.lungcan.2015.03.020. Epub 2015 Mar 28.

**6. Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.**

Koinis F, Nintos G, Georgoulas V, Kotsakis A.

*Expert Opin Pharmacother*. 2015;16(10):1505-19. doi: 10.1517/14656566.2015.1055248. Epub 2015 Jun 16.

**7. Small cell lung cancer (SCLC): no treatment advances in recent years.**

Koinis F, Kotsakis A, Georgoulas V.

*Transl Lung Cancer Res*. 2016 Feb; 5(1):39-50. doi: 10.3978/j.issn.2218-6751.2016.01.03.

**8. Effect of first-line treatment on myeloid-derived suppressor cells' subpopulations in the peripheral blood of non-small cell lung cancer patients.**

Koinis F, Vetsika E, Aggouraki D, Skalidaki E, Koutoulaki A, Gkioulmpasani M, Georgoulas V, Kotsakis A.

*Journal of Thoracic Oncology*, 2016 May 10; doi: 10.1016/j.jtho.2016.04.026

**9. Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).**

Matikas A, Kentepozidis N, Ardavanis A, Vaslamatzis M, Polyzos A, Emmanouilides Ch, Katsaounis P, Koinis F, Xynogalos S, Christopoulou A, Ziras N, Tegos T, Prinarakis E, Hatzidaki D, Georgoulas V, Kotsakis A; HORG's Lung Cancer Working Group.

*Cancer Chemother Pharmacol*. 2016 Aug;78(2):369-76. doi: 10.1007/s00280-016-3094-7.

- 10. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).**

Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulas V, Kotsakis A.

*Clin Transl Oncol.* 2016 Aug 4. [Epub ahead of print] doi: 10.1007/s12094-016-1532-y.

- 11. A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.**

Kotsakis A, Matikas A, Koinis F, Kentepozidis N, Varthalitis II, Karavassilis V, Samantas E, Katsaounis P, Dermitzaki EK, Hatzidaki D, Mavroudis D, Georgoulas V.

*Br J Cancer.* 2016 Sep 27;115(7):784-8. doi: 10.1038/bjc.2016.281.

- 12. Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.**

Pontikakis S, Papadaki C, Tzardi M, Trypaki M, Sfakianaki M, Koinis F, Lagoudaki E, Giannikaki L, Kalykaki A, Kontopodis E, Saridaki Z, Malamos N, Georgoulas V, Souglakos J.

*Pharmacogenomics J.* 2016 Oct 25. doi: 10.1038/tpj.2016.63. [Epub ahead of print]

- 13. Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients.**

Athanasios Kotsakis, Filippos Koinis, Afroditi Katsarou, Marianthi Gioulbasani, Despoina Aggouraki, Nikolaos Kentepozidis, Vassilis Georgoulas, Eleni-Kyriaki Vetsika.

*Sci Rep.* 2016 Dec 15;6:39247. doi: 10.1038/srep39247.

- 14. Lung cancer and tobacco smoking in Crete, Greece: reflections from a population-based cancer registry from 1992 to 2013.**

Sifaki-Pistolla D, Lionis C, Georgoulas V, Kyriakidis P, Koinis F, Aggelaki S, Tzanakis N.

*Tob Induc Dis.* 2017 Jan 19;15:6. doi: 10.1186/s12971-017-0114-2.

- 15. Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.**

Messaritakis I, Politaki E, Plataki M, Karavassilis V, Kentepozidis N, Koinis F, Samantas E, Georgoulas V, Kotsakis A.

*Lung Cancer.* 2017 Feb;104:16-23. doi: 10.1016/j.lungcan.2016.12.008. Epub 2016 Dec 14.



**16. TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC).**

Messaritakis I, Stoltidis D, Kotsakis A, Dermitzaki EK, Koinis F, Lagoudaki E, Koutsopoulos A, Politaki E, Apostolaki S, Souglakos J, Georgoulas V.

*Sci Rep.* 2017 Mar 28;7:45351. doi: 10.1038/srep45351.

**17. Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.**

Koinis F, Voutsina A, Kalikaki A, Koutsopoulos A, Lagoudaki E, Tsakalaki E, Dermitzaki EK, Kontopodis E, Pallis AG, Georgoulas V, Kotsakis A.

*Clin Transl Oncol.* 2017 Jun 19. doi: 10.1007/s12094-017-1702-6.

**18. Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.**

Koinis F, Agelaki S, Karavassilis V, Kentepozidis N, Samantas E, Peroukidis S, Katsaounis P, Hartabilas E, Varthalitis II, Messaritakis I, Fountzilias G, Georgoulas V, Kotsakis A.

*Br J Cancer.* 2017 Jun 27;117(1):8-14. doi: 10.1038/bjc.2017.137. Epub 2017 May 16.

**19. Prognostic value of chemotherapy-resistant CK19 mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.**

Milaki G, Messaritakis I, Koinis F, Kotsakis A, Apostolaki S, Dermitzaki EK, Perraki M, Hatzidaki D, Georgoulas V.

*Cancer Chemother Pharmacol.* 2017 Jul;80(1):101-108. doi: 10.1007/s00280-017-3339-0. Epub 2017 May 18.

**20. Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer.**

Messaritakis I, Politaki E, Kotsakis A, Dermitzaki EK, Koinis F, Lagoudaki E, Koutsopoulos A, Kallergi G, Souglakos J, Georgoulas V.

*PLoS One.* 2017 Jul 18;12(7):e0181211. doi: 10.1371/journal.pone.0181211. eCollection 2017.

**21. Lung cancer and annual mean exposure to outdoor air pollution in Crete, Greece.**

Sifaki-Pistolla D, Lionis C, Koinis F, Georgoulas V, Tzanakis N; On behalf of the Cancer Registry of Crete (CRC).

*Eur J Cancer Prev.* 2017 Jul 25. doi: 10.1097/CEJ.0000000000000407.

**22. A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer.**

Politaki E, Agelaki S, Apostolaki S, Hatzidaki D, Strati A, Koinis F, Perraki M, Saloustrou G, Stoupis G, Kallergi G, Spiliotaki M, Skaltsi T, Lianidou E, Georgoulas V, Mavroudis D.

*Cell Physiol Biochem.* 2017;44(2):594-606. doi: 10.1159/000485115. Epub 2017 Nov 20.

**23. Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group.**

Katsaounis P, Kotsakis A, Kentepozidis N, Polyzos A, Bakogeorgos M, Koinis F, Vamvakas L, Vardakis N, Kalbakis K, Boukovinas I, Varthalitis II, Prinarakis E, Georgoulas V, Souglakos J.

*Ann Gastroenterol.* 2018 Jan-Feb;31(1):65-70. doi: 10.20524/aog.2017.0215. Epub 2017 Nov 27

**24. Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer.**

Kallergi G, Vetsika EK, Aggouraki D, Lagoudaki E, Koutsopoulos A, Koinis F, Katsarlinos P, Trypaki M, Messaritakis I, Stournaras C, Georgoulas V, Kotsakis A.

*Ther Adv Med Oncol.* 2018 Jan 15;10:1758834017750121. doi: 10.1177/1758834017750121. eCollection 2018.

**25. Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib.**

Messaritakis I, Politaki E, Koinis F, Stolidis D, Apostolaki S, Plataki M, Dermitzaki EK, Georgoulas V, Kotsakis A.

*Sci Rep.* 2018 Feb 2;8(1):2238. doi: 10.1038/s41598-018-20502-1.

Updated complete list of publications at:

<https://www.ncbi.nlm.nih.gov/sites/myncbi/1ViPu6bGzfZ5D/bibliography/52420761/public/?sort=date&direction=ascending>

## **AUTHORSHIP IN BOOK CHAPTERS**

1. Book Title: International Manual of Oncology Practice, Book Subtitle: (iMOP) - Principles of Medical Oncology.  
Editors: Ramon Andrade de Mello, Alvaro Tavares, Giannis Mountzios.

Author of chapter “Asthenia”.

Publisher: *Springer International Publishing, 2015.*

## INVITED SPEAKER

1. Best of World Conference on Lung Cancer, 28<sup>th</sup> February – 1<sup>st</sup> March 2014, Athens, Greece  
“Trials regarding Small Cell Lung Cancer”
2. Hellenic Symposium on supportive care in cancer, 12-15<sup>th</sup> February 2015, Thessaloniki, Greece  
“Pathophysiology and treatment of cancer cachexia”
3. Best Of ASCO, event in Greece, 11-12 September 2015, Kalamata, Greece  
Presenter of 2 abstracts during Session 11: Lung Cancer, Non-Small Cell Lung Cancer
4. Best of San Antonio Breast Cancer Symposium, 8-9 January 2016, Athens, Greece  
“Translational Genomics/Clinical Application of Hereditary Multigene panels”
5. 18<sup>th</sup> Panhellenic Congress on Oncology, 18-21 February 2016, Thessaloniki, Greece  
“New agents for the management of cachexia in advanced cancer patients”
6. Overview on novel cancer treatments, 20-21 May 2016, Nauplio, Greece  
“CDK 4/6 inhibitors in breast cancer”
7. Yearly update of advances in medical oncology 2015, 27-28 May 2016, Athens, Greece  
“Biomarkers in NSCLC”
8. 15th Symposium on New Molecules in Cancer Therapeutics, 11-12 Nov 2016, Athens, Greece  
“Therapeutic algorithm for the treatment of prostate cancer”
9. 4th Symposium on Thoracic and Upper Aerodigestive Malignancies, April 6-9 2017, Athens, Greece  
“The epidemiology of EGFR mutations in non-small cell lung cancer in Greece”
10. Best of ASCO 2017, ANNUAL MEETING, event in Greece, 29-30 Sep 2017, Athens, Greece  
“Immunotherapy in NSCLC”
11. Masterclass on Tumor Biomarkers, 19-20 Oct 2017, Athens, Greece  
“Emerging biomarkers in prostate cancer”
12. 3rd Symposium on Advances in Cancer Immunology and Immunotherapy, 2-4 Nov 2017, Athens, Greece  
“New immunotherapeutic agents - Combination of immunotherapy treatments”

13. Annual meeting on cancer biology & New molecules in cancer therapeutics, 14-17 Dec 2017, Athens, Greece  
“Immune check point inhibitors: η ορθολογική χρήση τους στη καθημερινή κλινική πράξη”

## **MEMBER OF COORDINATING/SCIENTIFIC COMMITTEE**

1. New drugs in Oncology: Algorithms for the management of drug adverse reactions in clinical practice, 11 February 2016, Heraklion, Crete, Greece
2. 4th Symposium on Thoracic and Upper Aerodigestive Malignancies, April 6-9, 2017, Athens, Greece

## **MEMBER OF SCIENTIFIC SOCIETIES**

Member of the Hellenic Young Medical Oncologists Group (GYON) (since 2009)

Member of the EORTC Young Investigators Breast Cancer Group (since 2013)

Member of the European Society of Medical Oncology (ESMO Member) (since 2014)

Member of the Hellenic Oncology Research Group (HORG) (since 2015)

Member of the Hellenic Society of Medical Oncology (HeSMO) (since 2015)

Member of the American Society of Clinical Oncology (ASCO) (since 2015)

Member of MD Anderson Postdoctoral Association (PDA) (since 2016)